- Home
- USEA vs TXMD Comparison
USEA vs TXMD Comparison
Compare USEA & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USEA
- TXMD
- Stock Information
- Founded
- USEA 2004
- TXMD 2008
- Country
- USEA Greece
- TXMD United States
- Employees
- USEA N/A
- TXMD N/A
- Industry
- USEA Marine Transportation
- TXMD Biotechnology: Pharmaceutical Preparations
- Sector
- USEA Consumer Discretionary
- TXMD Health Care
- Exchange
- USEA Nasdaq
- TXMD Nasdaq
- Market Cap
- USEA 24.2M
- TXMD 21.7M
- IPO Year
- USEA N/A
- TXMD N/A
- Fundamental
- Price
- USEA $2.52
- TXMD $1.73
- Analyst Decision
- USEA Strong Buy
- TXMD
- Analyst Count
- USEA 1
- TXMD 0
- Target Price
- USEA $6.00
- TXMD N/A
- AVG Volume (30 Days)
- USEA 39.5K
- TXMD 15.1K
- Earning Date
- USEA 08-06-2024
- TXMD 08-12-2024
- Dividend Yield
- USEA 11.86%
- TXMD N/A
- EPS Growth
- USEA N/A
- TXMD N/A
- EPS
- USEA 0.85
- TXMD N/A
- Revenue
- USEA $46,276,000.00
- TXMD $996,000.00
- Revenue This Year
- USEA $34.90
- TXMD $605.07
- Revenue Next Year
- USEA $11.95
- TXMD $1.11
- P/E Ratio
- USEA $2.99
- TXMD N/A
- Revenue Growth
- USEA 86.18
- TXMD N/A
- 52 Week Low
- USEA $2.01
- TXMD $1.43
- 52 Week High
- USEA $3.00
- TXMD $3.73
- Technical
- Relative Strength Index (RSI)
- USEA 49.00
- TXMD 46.13
- Support Level
- USEA $2.45
- TXMD $1.72
- Resistance Level
- USEA $2.56
- TXMD $1.88
- Average True Range (ATR)
- USEA 0.05
- TXMD 0.10
- MACD
- USEA 0.00
- TXMD -0.00
- Stochastic Oscillator
- USEA 47.37
- TXMD 35.29
About USEA United Maritime Corporation
United Maritime Corp operates as a shipping company currently specializing in the seaborne transportation of dry bulk commodities. It currently operates one LR2 tanker vessel and three Capesize dry bulk vessels, two Kamsarmax dry bulk vessels, and three Panamax dry bulk vessels, with an aggregate cargo-carrying capacity of approximately 1,004,289 dwt.
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.